Hypereosinophilic syndrome (HES) represents an umbrella definition including a number of rare immuno-hematological conditions sharing a common background: persistent blood eosinophil count >1.5×109/L and evidence of eosinophil-mediated organ damage. Due to underlying multiple pathobiological mechanisms, not fully understood so far, the clinical presentation and manifestations might be heterogeneous and not specific. Accordingly, lab-work and imaging results may overlap with other conditions. As a consequence HES is under-recognised, with relevant diagnostic and therapeutic delay.The proposed Task Force (TF) on HES intends to pool together dedicated experts to plan focused initiatives and to provide EAACI and more generally the medical community the cutting edge knowledge to ultimately improve the standard of care of HES patients, even in the light of the recent approval and ongoing development of novel eosinophil-targeting treatment options.The TF aims to define priorities in terms of clinical and research needs and to produce a practical document supporting the recognition of HES in different settings (i.e. different sub-specialties, primary care) and promoting a multidisciplinary approach to HES patients. The TF has also the objective to explore health care professionals (HCPs) awareness, knowledge and attitudes towards HES through a survey, in order to facilitate networking within EAACI community, between HCPs and Patients, and with other Groups or Academies.

Committee

Chair: Florence Roufosse

Secretary: Marco Caminati